AbbVie Beats On Q4 Earnings, Skyrizi Sales Grows 76%, Annual Guidance Lags Consensus

  • AbbVie Inc ABBV has reported Q4 adjusted EPS of $3.60, up 16.9% Y/Y and beating the consensus of $3.56.
  • Overall sales increased 1.6% Y/Y (3.8% on an operational basis) to $15.12 billion, missing the consensus of $15.31 billion.
  • The immunology portfolio generated $7.92 billion in sales, +17.5% (+19.5% on an operational basis). Humira sales increased 4.6% to $5.56 billion. Skyrizi sales reached $1.58 billion (+76.1% Y/Y), and Rinvoq jumped 49% to $770 million.
  • Related: AbbVie, Eli Lilly Leave UK's Voluntary Medicines Pricing Agreement Over Increasing Prices.
  • Hematologic oncology portfolio sales were $1.63 billion, down 12.9% (-11.2% on an operational basis). Imbruvica sales decreased 19.5% to $1.12 billion. Venclexta revenues were up 5.7% to $516 million.
  • Sales from the neuroscience portfolio reached $1.71 billion, +3.4%. Aesthetics portfolio sales decreased 8.5% (-4.2% on an operational basis) to $1.29 billion, with $642 million in Botox sales for cosmetic uses.
  • Guidance: AbbVie expects FY23 adjusted EPS of $10.70-$11.10 versus the $11.65 estimate.
  • Price Action: ABBV shares are up 4.35% at $150.94 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!